Ferring Signs Global Agreement to Commercialise Novel Gene Therapy for Bladder Cancer Patients
SAINT-PREX, Switzerland–(BUSINESS WIRE)– rAd-IFN/Syn3, a novel gene therapy, is in Phase 3 development to treat high-grade non-muscle invasive bladder cancer patients, who are unresponsive to...